Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery. The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. […]